PARP Inhibitors for Cancer Therapy

PARP Inhibitors for Cancer Therapy provides a comprehensive overview of the role of PARP in cancer therapy. The volume covers the history of the discovery of PARP (poly ADP ribose polymerase) and its role in DNA repair. In addition, a description of discovery of the PARP family, and other DNA maintenance-associated PARPs will also be discussed. The volume also features a section on accessible chemistry behind the development of inhibitors. PARP inhibitors are a group of pharmacological inhibitors that are a particularly good target for cancer therapy. PARP plays a pivotal role in DNA repair and may contribute to the therapeutic resistance to DNA damaging agents used to treat cancer. Researchers have learned a tremendous amount about the biology of PARP and how tumour-specific defects in DNA repair can be exploited by PARPi. The "synthetic lethality" of PARPi is an exciting concept for cancer therapy and has led to a heightened activity in this area..

Preface -- Acknowledgements -- Contents -- Contributors -- Part I -- What Parp is and What it Does -- Chapter-1 -- History of the Discovery of Poly (ADP-ribose) -- 1.1 The Discovery of Poly (ADP-ribose) and of Its Associated Enzymes -- 1.2 Determination of the Molecular Structure of Poly (ADP-ribose) -- 1.2.1 The Discovery of Poly (ADP-ribose) Glycohydrolase -- 1.2.2 Poly (ADP-ribose) Shown to be Real and Not an Experimental Artefact -- 1.2.3 The Early International PARP Meetings -- 1.2.4 The Discovery of PARP Inhibitors and Elucidation of the Function of PARP in the Cellular Reaction to DNA Damage -- 1.2.5 PARP Inhibitors as Potential Anti-cancer Drugs -- 1.2.6 A Second Phase of PARP History the Deliberate Invention of New and More Powerful PARP Inhibitors for Potential Clinical Use -- 1.2.7 A Third Phase in PARP History the Current Period of PARP Science is Devoted to an Understanding of the Detailed Molecular Processes in Which the Various PARP Enzymes Participate -- References -- Chapter-2 -- Discovery of the PARP Superfamily and Focus on the Lesser Exhibited But Not Lesser Talented Members -- 2.1 Discovery of the PARP Superfamily (History, Characteristics, MART/PARPs, Nomenclature) -- 2.2 The macroPARPs: PARP-9, PARP-14, PARP-15 -- 2.2.1 Structure/Domains of macroPARPs -- 2.2.2 PARP-9 -- 2.2.2.1 PARP-9, a Transcription Co-Factor in IFNγ Signalling, Promoting Tumour Development -- 2.2.2.2 PARP-9 and the DNA Damage Response -- 2.2.3 PARP-14 -- 2.2.3.1 PARP-14, a Transcription Co-Factor -- 2.2.3.2 Roles of PARP-14 in Immune Response -- 2.2.3.3 PARP-14 and Cancer -- 2.3 PARP-10 -- 2.4 The CCCH-PARPs: PARP-7, PARP-12, PARP-13 -- 2.4.1 PARP-7 -- 2.4.2 PARP-13 -- 2.4.3 PARP-12 -- 2.5 vPARP -- 2.6 PARP-16 -- 2.7 PARP-6, PARP-8, PARP-11 -- 2.8 Conclusion: Targeting Novel PARP Family Members in Anticancer Strategies -- References -- Chapter-3..

Medienart:	E-Book

Erscheinungsjahr:	2015 ©2015
Erschienen:	Cham: Springer International Publishing AG ; 2015 ©2015

Reihe:	Cancer Drug Discovery and Development Ser.

Sprache:	Englisch

Beteiligte Personen:	Curtin, Nicola J. [VerfasserIn] Sharma, Ricky A. [Mitwirkende/r]

Links:	ebookcentral.proquest.com [lizenzpflichtig]

ISBN:	978-3-319-14151-0

Themen:	Drug interactions Electronic books Medicine Oncology

Anmerkungen:	Description based on publisher supplied metadata and other sources

Umfang:	1 online resource (590 pages)

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	1746132787